Restenosis of the CYPHER-Select, TAXUS-Express, and Polyzene-F nanocoated cobalt-chromium stents in the minipig coronary artery model

被引:19
作者
Radeleff, Boris [1 ]
Thierjung, Heidi [1 ]
Stampfl, Ulrike [1 ]
Stampfl, Sibylle [1 ]
Lopez-Benitez, Ruben [1 ]
Sommer, Christof [1 ]
Berger, Irina [2 ]
Richter, Goetz M. [1 ]
机构
[1] Univ Heidelberg, Dept Radiol, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, Dept Pathol, D-69120 Heidelberg, Germany
关键词
drug-eluting stent; inflammation; Polyzene-F; restenosis;
D O I
10.1007/s00270-007-9243-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose To date no direct experimental comparison between the CYPHER-Select and TAXUS-Express stents is available. Therefore, we investigated late in-stent stenosis, thrombogenicity, and inflammation, comparing the CYPHER-Select, TAXUS-Express, and custom-made cobalt chromium Polyzene-F nanocoated stents (CCPS) in the minipig coronary artery model. Methods The three stent types were implanted in the right coronary artery of 30 minipigs. The primary endpoint was in-stent stenosis assessed by quantitative angiography and microscopy. Secondary endpoints were inflammation and thrombogenicity evaluated by scores for inflammation and immunoreactivity (C-reactive protein and transforming growth factor beta). Follow-up was at 4 and 12 weeks. Results Stent placement was successful in all animals; no thrombus deposition occurred. Quantitative angiography did not depict statistically significant differences between the three stent types after 4 and 12 weeks. Quantitative microscopy at 4 weeks showed a statistically significant thicker neointima (p = 0.0431) for the CYPHER (105.034 +/- 62.52 mu m) versus the TAXUS (74.864 +/- 66.03 mu m) and versus the CCPS (63.542 +/- 39.57 mu m). At 12 weeks there were no statistically significant differences. Inflammation scores at 4 weeks were significantly lower for the CCPS and CYPHER compared with the TAXUS stent (p = 0.0431). After 12 weeks statistical significance was only found for the CYPHER versus the TAXUS stent (p = 0.0431). The semiquantitative immunoreactivity scores for C-reactive protein and transforming growth factor beta showed no statistically significant differences between the three stent types after 4 and 12 weeks. Conclusions The CCPS provided effective control of late in-stent stenosis and thrombogenicity in this porcine model compared with the two drug-eluting stents. Its low inflammation score underscores its noninflammatory potential and might explain its equivalence to the two DES.
引用
收藏
页码:971 / 980
页数:10
相关论文
共 29 条
[1]   Developing guidelines on the care and use of animals [J].
Bayne, K .
XENOTRANSPLANTATION: SCIENTIFIC FRONTIERS AND PUBLIC POLICY, 1998, 862 :105-110
[2]   Stent thrombosis late after implantation of first-generation drug-eluting stents - A cause for concern [J].
Camenzind, Edoardo ;
Steg, P. Gabriel ;
Wijns, William .
CIRCULATION, 2007, 115 (11) :1440-1455
[3]   Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model [J].
Carter, AJ ;
Aggarwal, M ;
Kopia, GA ;
Tio, F ;
Tsao, PS ;
Kolata, R ;
Yeung, AC ;
Llanos, G ;
Dooley, L ;
Falotico, R .
CARDIOVASCULAR RESEARCH, 2004, 63 (04) :617-624
[4]   TGFβ is active, and correlates with activators of TGFβ, following porcine coronary angioplasty [J].
Chamberlain, J ;
Gunn, J ;
Francis, SE ;
Holt, CM ;
Arnold, ND ;
Cumberland, DC ;
Ferguson, MWJ ;
Crossman, DC .
CARDIOVASCULAR RESEARCH, 2001, 50 (01) :125-136
[5]   Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months [J].
Drachman, DE ;
Edelman, ER ;
Seifert, P ;
Groothuis, AR ;
Bornstein, DA ;
Kamath, KR ;
Palasis, M ;
Yang, DC ;
Nott, SH ;
Rogers, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) :2325-2332
[6]   Pathological analysis of local delivery of paclitaxel via a polymer-coated stent [J].
Farb, A ;
Heller, PF ;
Shroff, S ;
Cheng, L ;
Kolodgie, FD ;
Carter, AJ ;
Scott, DS ;
Froehlich, J ;
Virmani, R .
CIRCULATION, 2001, 104 (04) :473-479
[7]   Stent thrombosis redux - The FDA perspective [J].
Farb, Andrew ;
Boam, Ashley B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (10) :984-987
[8]   Analysis of pigmented villonodular synovitis with genome-wide complementary DNA microarray and tissue array technology reveals insight into potential novel therapeutic approaches [J].
Finis, K ;
Sültmann, H ;
Ruschhaupt, M ;
Buness, A ;
Helmchen, B ;
Kuner, R ;
Gross, ML ;
Fink, B ;
Schirmacher, P ;
Poustka, A ;
Berger, I .
ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :1009-1019
[9]   Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents [J].
Finn, AV ;
Kolodgie, FD ;
Harnek, J ;
Guerrero, LJ ;
Acampado, E ;
Tefera, K ;
Skorija, K ;
Weber, DK ;
Gold, HK ;
Virmani, R .
CIRCULATION, 2005, 112 (02) :270-278
[10]   C-reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents [J].
Gaspardone, A ;
Versaci, F ;
Tomai, F ;
Citone, C ;
Proietti, I ;
Gioffrè, G ;
Skossyreva, O .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (09) :1311-1316